Daihan Pharmaceutical Co. (023910.KS)

KSC Healthcare Medical - Pharmaceuticals

51.8

ValueMarkers Composite Index

Top 37%#28,258 of 45,178

DCF data not available

Piotroski

0/9

Weak

Beneish

Altman

DCF Value

N/A

ROIC

P/E

6.1

Value

Unlock Full Analysis · Free Trial

Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Dai Han Pharm. Co., Ltd. manufactured the first infusion as the basis of the national health, opening a new horizon for medical companies and grew as a representative infusion manufacturer of Korea

CEO: Yoon-Woo Lee675 employeesKRwww.daihan.com/eng

Deep Dive Analysis

DCF Analysis

Intrinsic value estimate, margin of safety, and key valuation metrics.

Graham: $0.00

Piotroski F-Score

9-point financial strength test across profitability, leverage, and efficiency.

F-Score: 0/9

Quality Triple Check

Piotroski F-Score + Altman Z-Score + Beneish M-Score combined assessment.

F: 0/9

Valuation Analysis

Complete multiples breakdown - P/E, P/B, EV/EBITDA, yield metrics, and intrinsic value.

P/E: 6.1P/B: 0.6EV/EBITDA: 3.0